| Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. | |
| | |
MedLine Citation:
|
PMID: 21070297 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
What is known and Objective: The efficacy of sibutramine has been demonstrated in randomized trials in obese/overweight patients including those with type 2 diabetes mellitus (T2DM). Our objective was to evaluate the effects of 1-year treatment with sibutramine compared to placebo on body weight, glycaemic control, lipid profile, and inflammatory parameters in type 2 diabetic patients. Methods: Two hundred and forty-six patients with uncontrolled T2DM [glycated haemoglobin (HbA(1c) ) >8·0%] in therapy with different oral hypoglycaemic agents or insulin were randomized to take 10 mg of sibutramine or placebo for 12 months. We evaluated at baseline, and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA(1c) , fasting plasma glucose (FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), triglycerides (Tg), leptin, tumour necrosis factor-α (TNF-α), adiponectin (ADN), vaspin, high sensitivity C-reactive protein (Hs-CRP). Results and Discussion: We observed a decrease of body weight after 9 and 12 months in the group treated with sibutramine, but not in the control group. Regarding glycaemic and lipid profile, although there are differences seen over time within each of the groups, we did not obtain any significant differences between the two groups. Both placebo and sibutramine gave a similar improvement of HOMA-IR, leptin, TNF-α, ADN, and Hs-CRP. No vaspin variations were observed in either group. What is new and Conclusion: Sibutramine resulted in a decrease in body weight at 9 months and at 12 months that was not observed with placebo. Although there were differences seen over time within each of the groups, there were no significant differences between groups for any other parameter that we measured. |
| | |
Authors:
|
G Derosa; P Maffioli; I Ferrari; I Palumbo; S Randazzo; A D'Angelo; A F G Cicero |
Related Documents
:
|
17556867 - Association of insulin resistance and nocturnal fall of blood pressure in gh-deficient ... 20578127 - Comparison of surrogate and direct measurement of insulin resistance in chronic hepatit... 20129687 - Changes of serum omentin-1 levels in normal subjects and in patients with impaired gluc... 10471657 - Determination of glucose in dried serum samples by fourier-transform infrared spectrosc... 12595097 - Decreased activity and impaired induction of nitric oxide synthase by lipopolysaccharid... 1477987 - Copper metabolism--a factor in gestational diabetes? |
Publication Detail:
|
Type: Journal Article Date: 2010-11-12 |
Journal Detail:
|
Title: Journal of clinical pharmacy and therapeutics Volume: 36 ISSN: 1365-2710 ISO Abbreviation: J Clin Pharm Ther Publication Date: 2011 Oct |
Date Detail:
|
Created Date: 2011-09-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8704308 Medline TA: J Clin Pharm Ther Country: England |
Other Details:
|
Languages: eng Pagination: 592-601 Citation Subset: IM |
Copyright Information:
|
© 2010 The Authors. JCPT © 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Internal Medicine and Therapeutics, University of Pavia, Pavia "G. Descovich"Atherosclerosis Study Center, Department of Internal Medicine, Aging and Kidney Diseases, University of Bologna, Bologna, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy and safety of a pharmacist-managed inpatient anticoagulation service for warfarin initiatio...
Next Document: The uncertainty of nanotoxicology: report of a Society for Risk Analysis Workshop.